CHOLETEC (mebrofenin) by Bracco is clinical pharmacology mebrofenin is an iminodiacetic acid (hida) derivative with no known pharmacologic action at the recommended doses. First approved in 1987.
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
CHOLETEC (Mebrofenin) is a Technetium Tc 99m-labeled iminodiacetic acid (HIDA) derivative used for hepatobiliary imaging to assess liver function and biliary tract patency. It contains no pharmacologic action at diagnostic doses and works as a radiopharmaceutical tracer that is rapidly cleared by the hepatobiliary system. The drug visualizes the liver, hepatic ducts, gallbladder, and intestines in patients suspected of having biliary obstruction or cholecystitis.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team likely focused on defending market share and managing transition.
CLINICAL PHARMACOLOGY Mebrofenin is an iminodiacetic acid (HIDA) derivative with no known pharmacologic action at the recommended doses. Following intravenous administration in normal subjects, Technetium Tc 99m Mebrofenin was rapidly cleared from the circulation. The mean percent injected dose…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CHOLETEC at Bracco? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on CHOLETEC offers stability in a niche diagnostic imaging segment but limited growth opportunity given LOE approach and zero linked job openings. Career trajectory is defensive—suited for professionals seeking to manage mature products, optimize payer relationships, or transition into emerging diagnostic platforms.